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1. Introduction
Late graft loss remains a major obstacle to successful long-term kidney allograft transplanta‐
tion. The factors contributing to late graft loss include immunological (cellular and/or antibody
mediated injuries) and non-immunological (donor disease, recurrent disease, peri-transplant
ischemia, viral infection or drug toxicity) factors (Smith et al., 2006).
For decades, T cells were considered as the primary contributors to acute as well as chronic
rejection after organ transplantation.
The role of antibody in rejection of transplanted organs was the subject of debate in the early
days of transplantation. Peter Gorer was the first to describe the role of antibody and Peter
Medwar championing cell-mediated immunity. Following the death of Gorer's in 1961, the
concept of antibody-mediated rejection faded into the background. However, by 1997
demonstration of the relative sensitivity and specificity of C4d staining in peritubular capil‐
laries in identifying antibody mediated rejection raised the hope that a rigorous morphological
classification could be devised.
Allo-antibodies to HLA class I or II and other antigens expressed by endothelium cause a
variety of effects on renal transplants, ranging from acute to chronic rejection, and even
apparent graft acceptance (accommodation). Recognition of these conditions and appropriate
therapy requires demonstration of C4d in biopsies, commonly confirmed by tests for circulat‐
ing allo-antibody (Lefaucheur et al., 2010).
Pre-existing (Amico et al., 2009) or post transplant (Cantarovich et al., 2011; Lefaucheur et al.,
2010) development of donor specific antibodies (DSA) lead to Acute AMR occurred in 8% of
kidney transplant patients. The 5-year graft survivals of patients who had an episode of AMR
were significantly worse than that of the remaining transplant population. The relative risk
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(RR) for graft loss for patients who had an episode of AMR was around 4 times as compared
with patients without AMR. Importantly, even in patients without any episode of AMR, the
presence of anti-HLA-DSA on the peak serum was still associated with a significantly lower
graft survival as compared with patients without anti-HLA-DSA (Amico et al., 2009; Cantar‐
ovich et al., 2011; Lefaucheur et al., 2010).
The recently described entity of subclinical AMR (Gloor et al., 2006; Haas et al., 2007) in which
progressive morphologic lesions are found on biopsy in the absence of overt clinical rejection
may account for this different course. A recent study demonstrated that subclinical AMR is a
frequent finding in patients with preformed HLA-DSA (31.1% at 3 months) and is associated
with worse GFR at 1 year (Loupy et al., 2009). These progressive lesions lead to chronic humoral
rejection, first described in 2001 (Regele et al., 2002) and now recognized to be a distinct cause
of late graft dysfunction and loss (Gloor et al., 2007; Regele et al., 2002).
Antibody-mediated rejection has become clinically critical because this form of rejection is
usually unresponsive to conventional anti-rejection therapy, and therefore, it has been
recognized as a major cause of allograft loss. Although desensitization protocols have enabled
transplantation across donor-specific antibody barriers in a growing number of cases (Haas et
al., 2007; Jordan, 2006), these protocols are neither consistently efficacious nor standardized.
It reflects an incomplete understanding of the pathogenesis of alloantibody-induced injury as
a major cause of allograft loss. Furthermore, patients treated with these modalities persist in
having a high risk of multiple AMR episodes and lower graft long term survival compared to
antibody free patients.
2. Natural course
In 1968, when kidney transplant patients were first examined for the development of anti‐
bodies after graft failure, antibodies were detected in 11 (38%) of 29 patients who had rejected
their grafts (Morris et al., 1969).
The fact that some patients in desensitization protocols developed AMR and others with
similar levels of DSA at baseline did not, has remained unexplained due to the lack of detailed
studies of these patients post transplant. Burns et al. (Burns et al., 2008) aimed to define the
natural history of AMR in highly sensitized patients undergoing positive cross-match kidney
transplantation. They found that the serum DSA level after transplantation was the major
determinant of AMR. Patients who developed high levels of DSA within the first month after
transplantation almost invariably developed acute humoral rejection (AHR), whereas those
who maintained low levels were rejection-free. Importantly, more than half of the patients who
had high levels of DSA at baseline did not develop high levels of DSA after transplantation.
Almost all patients, including those who developed AMR, had a significant decrement or even
disappearance of DSA early after transplantation (Gloor et al., 2004; Zachary et al., 2005). This
finding that increases in DSA levels in AMR may be transient and self-limited in many patients
presents difficulties in assessing the effectiveness of therapy aimed at treating AMR.
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During the 12th International Histocompatibility workshop, a multicenter prospective study
was initiated to test patients with functioning kidney transplants once for HLA antibodies
post-transplantation. The 806 patients without HLA antibodies, had a subsequent 4 year graft
survival of 81%, compared with 58% for 158 patients with HLA antibodies [the presence of
anti-HLA antibodies led to 5% allograft loss every year; therefore, after 4 years, 20% of the
grafts will be lost ]( Terasaki et al., 2007).
Among 512 patients followed for 1 year post-testing in Sao Paulo, 12% of antibody positive
patients lost their grafts, whereas graft failure occurred in only 5.5% of those without HLA
antibodies (P=0.03) (Campos et al., 2006). These results have been updated, demonstrating that
at 3 years post-transplantation, patients without HLA antibodies had a 94% survival rate
compared with 79% for those with HLA class II antibodies (Gerbase-DeLima et al., 2007).
In a large multicentre trial, HLA-specific antibodies were detected in 21% of patients with renal
allografts and 14–23% of patients with heart, liver or lung allografts (Terasaki & Ozawa,
2004). Of 2,278 renal-allograft recipients who were followed prospectively, graft failure at 1
year occurred more frequently in patients who developed alloantibodies than in those who
did not (8.6% versus 3.0%). Several studies have reported that de novo antibodies that are
specific for graft HLA class I and class II molecules are a risk factor for premature graft loss as
a consequence of renal and cardiac chronic arteriopathy (Michaels et al., 2003; Pelletier et al.,
2002; Piazza et al., 2001).
For example, during a 5-year follow-up period, donor-reactive antibodies were present in 51%
of patients with graft failure compared with 2% of stable control individuals. The presence of
antibodies preceded graft failure in 60% of cases (Worthington et al., 2003). Worthington et al
(Worthington et al., 2001) showed that among 12 patients who developed ELISA-detected HLA
antibodies post-transplantation, 92% of the grafts failed, whereas among the 64 patients who
remained negative, only 11% of the grafts failed (P<0.001).
So, circulating HLA-specific antibodies are typically present months to years before graft
dysfunction, indicating that antibody-mediated graft injury might be slow to develop.
3. Pathogenesis and mechanism
The pathogenesis of late renal allograft loss is heterogeneous and difficult to diagnose.
How alloantibody and complement activation promote glomerulopathy, arteriopathy and
fibrosis is incompletely clear. Only in the past 7 years, a potential role of alloantibodies for
chronically deteriorating graft function has been postulated.
Alloantibodies are now appreciated as important mediators of acute and chronic rejection,
differing in pathogenesis, or “nature,” from T cell–mediated rejection.
Alloantibodies preferentially attack a different “location,” namely the peritubular and
glomerular capillaries, in contrast to T cells, which characteristically infiltrate tubules and
arterial endothelium.
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Antibody-mediated rejection generally has a worse prognosis and requires different ap‐
proaches to treatment and prevention than the usual T cell–mediated rejection.
Antibody induces rejection acutely through the fixation of complement, resulting in tissue
injury and coagulation. In addition, complement activation recruits macrophages and
neutrophils, causing additional endothelial injury. Antibody and complement also induce
gene expression by endothelial cells, which is thought to remodel arteries and basement
membranes, leading to fixed and irreversible anatomical lesions that permanently compromise
graft function.
3.1. Antigenic targets
The main antigenic targets of antibody-mediated rejection are MHC molecules (both class I
and class II) (Erlich et al., 2001) and the ABO blood-group antigens (Race & Sanger, 1958). MHC
class I molecules are found at the surface of all nucleated cells, including endothelial cells. By
contrast, the distribution of MHC class II molecules is more limited. These molecules are
constitutively expressed at the surface of B cells, dendritic cells (DCs) and microvascular
endothelial cells (the last applies to humans but not mice) and are expressed by other cells
depending on the stimuli that they have been exposed to and their transcriptional activation.
The extreme polymorphism of MHC class I and class II polypeptides (more than 1,600 alleles
in humans) aids their main function, which is antigen presentation to T cells.
Production of HLA specific alloantibodies depends on exposure to HLA molecules as a
consequence of pregnancy, blood transfusion or transplantation. These antibodies are mainly
of the IgG class. Blood-group antigens, most importantly the A and B antigens, are carbohy‐
drate epitopes on glycolipids and glycoproteins that are present at the surface of most tissues,
including erythrocytes and endothelial cells. Antibodies that are specific for A or B antigens
arise ‘naturally’ in normal individuals who are not of the A and/or B blood group in response
to antigens from the environment, and they are usually of the IgM class (Colvin & Smith, 2005).
Antibodies to class I MHC antigens can stimulate endothelial and smooth muscle proliferation
and expression of FGF receptors (Bian & Reed, 2001). Soluble terminal complement compo‐
nents (C5b-9) trigger the production of FGF and PDGF by endothelial cells (Benzaquen et al.,
1994). Thus antibodies and activated complement might induce gene products that promote
endothelial activation and injury with consequent basement membrane duplication and
arterial smooth muscle proliferation and thickening until finally, the characteristic atheroscle‐
rosis lesion of chronic rejection results in obstruction (Jin et al., 2002; Reed, 2003).
In addition to MHC molecules and blood-group antigens, minor histocompatibility antigens
might also be targets of antibody-mediated rejection. Minor histocompatibility antigens, which
were originally defined in mice by their ability to cause prompt skin-graft rejection, are also
thought to be relevant as targets of graft-versus-host disease and as tumor antigens (Chao,
2004). In animal studies, non-MHC-specific antibodies can cause endothelial-cell apoptosis
and graft rejection (Derhaag et al., 2000; Wu et al., 2002).
However, in humans, the molecular characterization of these antigens is limited.
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MICA (MHC-class-I-polypeptide-related sequence A), one of the few potential endothelial-
cell surface alloantigens, has been defined at the molecular level (Kooijmans-Coutinho et al.,
1996).
MICA is a polymorphic non-classical MHC molecule. Antibody that is specific for MICA
(MHC-class-I-polypeptide-related sequence A) can be detected in renal-allograft recipients
and is associated with later rejection and graft loss (Mizutani et al., 2005; Sumitran-Holgersson
et al., 2002) that was demonstrated by Zou and coworkers (Zou et al., 2007) who found that
antibodies against minor histocompatibility antigens such as MICA may be associated with a
poorer graft outcome.
Antibodies that recognize self-proteins might also contribute to graft injury. For example,
autoantibody that is specific for the angiotensin II type 1 receptor, which is expressed by
vascular smooth muscle, has been associated with severe hypertension, graft dysfunction and
fibrinoid arterial necrosis of human renal allografts (Dragun et al., 2005).
Several  studies have shown that  circulating anti-HLA class I  or  II  antibodies,  either do‐
nor reactive (Worthington et al.,  2003; Hourmant et al.,  2005) or de novo non–donor re‐
active  (Hourmant  et  al.,  2005;  Terasaki  &  Ozawa,  2005),  are  found  in  a  substantial
fraction of renal allograft recipients, and these are associated with later graft loss. Retro‐
spective studies demonstrated that de novo appearance of DSA was associated with poor
graft outcome (Colvin, 2007).  One study in more than 2000 patients prospectively estab‐
lished the risk of circulating alloantibodies for graft survival after 1 and 2 years (Terasa‐
ki & Ozawa, 2005).
3.2. B- lymphocytes
B cells are not just plasma cell precursors, but represent an important population of anti‐
gen-presenting  cells  particularly  efficient  in  the  situation  of  a  sensitized  recipient,  be‐
cause they have specific immunoglobulin as an antigen-specific receptor on their surface,
which  leads  to  efficient  uptake  and  presentation  of  donor  antigens  to  T  cells  (Noorch‐
ashm et al.,  2006). Indeed, an increased frequency of alloantigen-specific B cells in sensi‐
tized recipients has been reported (Zachary et al., 2007). Therefore, targeting these B cells
will also interfere with activation of indirectly allo-reactive T cells, which play an impor‐
tant role in chronic allograft rejection.
In sensitized allograft recipients with DSA, sensitization has always occurred on the level of
B and T cells; because B cells need T help to produce alloantibodies of IgG isotype as measured
by the Luminex technology. Therefore, a combined pathogenesis of rejection must always be
postulated, even if not all the pathologic criteria are fulfilled (Fehr et al., 2009).
However,  failure  to  demonstrate  DSA does  not  rule  out  a  contribution of  antibodies  to
the pathologic process, because absorption of antibodies by the allograft may result in a
lack  of  circulating  DSA (Martin  et  al.,  2005).  Alternatively,  DSA against  non-HLA anti‐
gens or HLA-DP could explain the missing ELISA reactivity in the presence of increased
cytotoxic  anti-B-cell  reactivity  and  ongoing  antibody-mediated  rejection  (Arnold  et  al.,
2005; Opelz, 2005; Zou et al., 2007).
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The combination of alloantibody, basement membrane multilamination, C4d, and duplication
of the GBM has been termed the “ABCD tetrad” by Solez and colleagues (Solez et al., 2007).
3.3. Plasma cells
During AMR, it is likely that a portion of the DSA found in the serum is due to ongoing
antibody production by pre-existing plasma cells. In addition, the observed increase in DSA
during AMR suggests that conversion of allospecific memory B cells to plasma cells also may
play a role. Unfortunately, no studies of the activity of memory B cells during AMR exist.
Despite this, several groups have developed protocols to treat AMR based on their presumed
impact on either B cells or plasma cells (Stegall & Gloor, 2010).
3.4. Presence of antibodies with good function
It is a common observation and “complaint” that some patients with HLA antibodies have
excellent kidney graft function. The exact frequency of this occurrence has been documented
to be about 20% in studies of 2658 patients with functioning grafts (Terasaki et al., 2007) Thus,
at any transplant center roughly 20% of patients would likely have antibodies and good
function.
According to prospective studies, when 158 patients with antibodies were followed for as long
as 4 years, their graft survival was 58% as compared with 81% for 806 patients without
antibodies (Terasaki et al., 2007).
Significantly,  the  presence  of  antibodies  did  not  foretell  immediate  or  certain  graft  fail‐
ure.  Studies by Worthington et al.  (Worthington et al.,  2007) have shown that the mean
time from antibody development  to  failure  for  class  I  antibodies  was  2.7  years  and 3.9
years for class II  antibodies.  Additionally,  antibodies causing humoral rejection may not
appear until as many as may reach up to 13 years (Kamimaki et al., 2007), or even after
26 years (Weinstein et al., 2005) posttransplant. The reason for this long interval between
antibody appearance and graft failure is the time needed for the endothelial walls of ar‐
teries  to  hypertrophy  and  close  the  lumen,  or  for  the  tubules  to  disappear  because  of
peritubular  capillary  damage produced by antibodies  (Shimizu et  al.,  2002).  In  both  in‐
stances,  defense mechanisms could be triggered as the endothelium is damaged and re‐
pair mechanisms are triggered (Jin et al., 2005).
4. Accommodation
Transplantation across an ABO barrier, which normally precipitates hyperacute rejection, has
been done successfully in many centers, using special protocols to deplete naturally occurring
anti–blood group antibodies.
The phenomenon of accommodation, in which the graft acquires resistance to humoral injury
and continues to function well despite the continued presence of antibody against a target
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antigen expressed on graft endothelium, is well documented in ABO-incompatible kidney
transplants (Park et al., 2003; Platt, 2002).
Alexandre and colleagues (Alexandre et al., 1987) initially observed accommodation in
recipients of an ABO-incompatible renal allograft. Transient depletion of the circulating
antibodies that are specific for these blood-group antigens at the time of transplantation allows
immediate graft survival without hyperacute rejection.
A rebound of antibody concentrations (primarily IgM) within the first 10 days occurs to‐
gether  with rejection in 90% of  cases.  However,  after  21 days,  for  the remaining grafts,
there is no correlation between the occurrence of rejection and the antibody titre (Park et
al.,  2003;  Shishido et  al.,  2001).  Even if  the  antibody titre  returns  to  pre-transplantation
levels or higher, the grafts continue to function. It has been proposed that in these cases,
complement regulatory proteins and/or other control mechanisms may interrupt the com‐
plement cascade distal to the generation of C4d, so the persistence of C4d on graft endo‐
thelium  represents  a  marker  for  the  arrest  of  the  complement  cascade  rather  than
ongoing complement-mediated graft injury (Williams et al., 2004).
As suggested by Platt (Platt, 2002), careful histologic and immunohistologic study may help
to answer this question and address any potential role of complement in the accommodation
process. Accommodation in ABO-incompatible grafts is not due to a change in the nature of
the antibody or loss of the target antigen in the graft, because C4d is deposited in the renal
microcirculation.
At a cellular level, accommodation may occur via multiple mechanisms, including internali‐
zation, downregulation, inactivation, and inhibition of the target antigen (Colvin & Nickeleit,
2006; Colvin & Smith, 2005).
Studies in mice show that, in the absence of T-cell help, B cells that are exposed to incompatible
carbohydrate antigens on allografts differentiate into cells that can produce non-complement-
fixing antibody which potentially competes with complement-fixing antibody, and these B
cells gradually become tolerant after prolonged exposure (Ogawa et al., 2004).
In  HLA-mismatched  grafts,  alloantibodies  can  be  found in  the  absence  of  clinical  graft
dysfunction, thereby fitting the definition of accommodation. However, patients with cir‐
culating  HLA-specific  antibody  have  a  greater  likelihood  of  later  graft  loss,  indicating
that,  if  accommodation  occurs,  then  it  is  either  transient  or  insufficient  to  prevent
CAMR. Long-term, complete  accommodation has not  been documented for  MHC mole‐
cules,  and  the  phenomenon might  therefore  be  partly  determined by  the  nature  of  the
antigen (Colvin & Smith, 2005). Accommodation may have different degrees of effective‐
ness  and  stability  (gradations),  ranging  from  none  (hyperacute  rejection),  to  minimal
(acute rejection), substantial (chronic rejection), or complete (stable accommodation) (Col‐
vin, 2007). The minimal features that indicate transformation from accommodation to re‐
jection  have  yet  to  be  defined  and  drugs  that  promote  more  effective  accommodation
would potentially be useful clinically.
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5. Stages of antibody-mediated rejection
At a National Institutes of Health (United States) consensus conference, draft criteria were
established for antibody-mediated rejection and for four theoretical stages in the development
of CAMR (Takemoto et al., 2004) as shown in FIG. 1 (Colvin & Smith, 2005).
Figure 1. Proposed stages of antibody-mediated rejection (Reproduced with permission from Nature Publishing
Group).
According to this model, the first evidence of an antibody-mediated response is the de novo
generation of donor-reactive antibodies (stage I). In many circumstances and for unknown
reasons, donor-reactive antibodies do not elicit AAMR.
The next stage (stage II) shows evidence of antibody reactivity and complement activation in
the graft, with C4d deposition in peritubular or glomerular capillary endothelium. At this
stage, there is no evidence of pathological or clinical injury in the graft. Both stage I and stage
II fit the criteria for accommodation and are therefore not necessarily predestined to lead to
graft injury. In stage III, in addition to positive staining for C4d, there are identifiable patho‐
logical changes, but graft function is still normal (that is, there is subclinical rejection). Finally,
in stage IV, in addition to positive staining for C4d and pathological changes, graft dysfunction
occurs. The interval between stages can be long and variable, and it is not known whether
progression is inexorable (Colvin & Smith, 2005).
6. Pathology
The past 20 years have seen major advances in the understanding of the effects of anti-
donor antibodies on renal allografts at various stages after transplantation. These advan‐
ces  have been due in  large  part  to  pathologic  examination of  both early  and late  renal
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allograft  biopsies,  including  both  routine  histologic  evaluation  and immunohistology  to
detect complement split products.
6.1. Acute antibody mediated rejection
As pathologists have become increasingly adept at diagnosing antibody-mediated rejection
(AMR) on allograft biopsies, substantial progress has been made in the treatment of AMR and
in successful renal transplantation in recipients with pre-existing antibodies against donor
blood group (ABO) and/or major histocompatibility (HLA) antigens. It has become critical to
develop standardized criteria for the pathological diagnosis of AMR.
The diagnostic criteria for acute humoral rejection (AMR; acute antibody-mediated rejection).
Patients with AHR present with an acute loss of graft function that often arises in the first few
weeks after transplantation and cannot be distinguished from cell-mediated rejection on
clinical grounds (Halloran et al., 1992; Takemoto et al., 2004). AMR can also develop years after
transplantation, often triggered by a decrease in immunosuppression (iatrogenic, noncompli‐
ance, or malabsorption). Presensitization is the major risk factor, but most of the patients with
AMR had a negative cross-match. AMR has occurred with all immunosuppression regimens,
even profoundly depleting therapy (Lorenz et al., 2004). The first clue that circulating anti–
class I HLA antibody caused a different pattern of acute rejection came from the studies of
Halloran’s group in Edmonton (Halloran et al., 1992). These investigators showed that
neutrophils in peritubular capillaries (PTC) and glomerular capillaries are strongly associated
with circulating anti-donor HLA antibodies. Other features, such as fibrinoid necrosis of
arteries and microthrombi, are also more common. However, none of these features is specific.
The pathology of AMR has a wide spectrum and can easily be missed by histologic criteria
alone. Renal biopsies may show acute cellular rejection, acute tubular injury, or thrombotic
microangiopathy. Neutrophils in capillaries are characteristically but not always found.
Macrophages are now recognized as a common intracapillary cell in AMR in kidney (Tinckam
et al., 2005) and heart (Lepin et al., 2006) allografts. Typically, the PTC are dilated. Fibrinoid
necrosis is found in a minority of cases (approximately 10 to 20%). A component of acute
cellular rejection may also be present, as manifested by a prominent mononuclear infiltrate,
tubulitis, or endarteritis. These lesions are generally not attributable to antibody alone. Treg
cells (FOXP3+) are rarer in the infiltrate than in cell-mediated rejection, perhaps contributing
to the poorer prognosis in AMR (Veronese et al., 2007). Microthrombi and interstitial hemor‐
rhage also sometimes occur. The PTC and glomerular endothelium shows a variety of
ultrastructural changes, including loss of fenestrations, detachment from the basement
membrane, lysis, and apoptosis; complete destruction of capillaries can occur, leaving
thickened laminated basement membranes (Liptak et al., 2005). Immunofluorescence (IF)
curiously does not often show antibody or C3 deposition in the vessels. However, IF does show
C4d in the majority of the PTC as a bright ring pattern, using a mAb in cryostat sections (Collins
et al., 1999; Mauiyyedi et al., 2001, 2002). Immunohistochemistry (IHC) works in formalin-
fixed, paraffin-embedded tissues with a polyclonal antibody (Lorenz et al., 2004). By immu‐
noelectron microscopy, C4d is detected on the surface of the endothelial cells and in
intracytoplasmic vesicles (Regele et al., 2002). Antibodies that react to non-C4d portions of the
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C4 molecule do not show PTC deposition, arguing that what is detected in tissues is primarily
C4d (Seemayer et al., 2006).
6.2. Chronic antibody mediated rejection
Chronic AMR is now included in the newest update of the Banff 07 classification of renal
allograft pathology with the following criteria: [1]morphological changes as glomerular
double contours compatible with transplant glomerulopathy (TPG) and severe PTC basement
membrane multilayering, interstitial fibrosis and tubular atrophy with or without PTC loss,
and fibrous intimal thickening in arteries without internal elastica duplication; [2] diffuse C4d
deposition in PTCs; and [3] presence of DSA (Solez et al.,2008). Not all these criteria are always
fulfilled in an individual patient at every given time point (Fehr et al., 2009).
PTC  basement  membrane  multilayering  correlates  highly  with  TPG,  and  most  of  TPG
have evidence of either C4d-positive staining or DSA. However, the proposed criteria do
not apply to all situations of chronic active antibody-mediated rejection. Chronic AMR is
distinct  from  acute  AMR  in  that  no  acute  inflammation  (neutrophils,  edema,  necrosis,
thrombosis) is present. However, cellular activity is often reflected by increased mononu‐
clear  cells  in  glomerular  capillaries  and  PTC  (Colvin,  2007).  The  Banff  criteria  require
PTC C4d positivity for diagnosis of  ABMR as well  as microcirculation injury.  However,
C4d is  not  a  sensitive  marker  of  chronic  ABMR,  and in  many patients  with  transplant
glomerulopathy,  C4d  staining  is  negative  in  the  presence  of  anti-HLA  DSA.  Therefore,
the recent update of the Banff classification introduced the diagnostic category of “suspi‐
cious for  ABMR.” It  is  defined with the presence of  morphologic evidence of  antibody-
mediated tissue injury and positive  anti-HLA antibody with negative C4d,  or  PTC C4d
positivity in the absence of alloantibody (Solez et al., 2008).
7. Markers of antibody mediated rejection
7.1. Histopathologic detection of C4d
Feucht et al. (Feucht et al., 1993) in Munich showed that peritubular capillary (PTC) C4d
deposition in renal transplant biopsies is strongly associated with a poor prognosis and raised
the possibility that antibodies were responsible. Currently, C4d has been adopted as a marker
of antibody-mediated rejection (Racusen et al., 2003). The justification for the selection of C4d,
a split product of C4, as a marker for AMR comes from its position in the cascade of complement
activation. C4d, a split product of the classical pathway of complement activation, is present
covalently bound on tissue near the sites of complement activation by alloantibody, e.g.,
vascular endothelial cell membrane.
C4d deposition in renal peritubular capillaries is strongly associated with circulating antibody
to donor HLA class I or class II antigens (Bohmig et al., 2002; Haas et al., 2006) and is currently
the best single marker of complement-fixing circulating antibodies to the endothelium.
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7.2. C4d detection pitfalls
C4d is not a magic marker for antibody-mediated rejection and in many patients with
transplant glomerulopathy. It is negative in the presence of anti-HLA DSA. Another issue with
chronic active antibody-mediated rejection is non-HLA antibody induced rejection without
complement fixation of C4d. Moreover, it was shown in many studies that focal C4d staining
was not a reliable indicator of AMR (Kayler et al., 2008), and it is not a guarantee of AMR:
diffuse C4d staining can occur with no morphologic injury or impaired outcome in ABO-
incompatible allografts (Solez et al., 2008). Another important problem is the significance of
positive C4d staining in the peritubular capillaries (PTC) and glomerular capillaries.
There are significant data to show that C4d positivity is usually long-lasting but is not
permanent. C4d staining can change from negative to positive and vice versa within days to
weeks. The detection of C4d signifies a humoral alloresponse in a subgroup of kidney
transplants, which is often associated with signs of cellular rejection (Nickeleit et al., 2002). It
is not clear how long C4d deposits persist in the absence of continued DSA production. One
study reported that C4d deposits were no longer detectable on repeat biopsy performed 2–3
weeks after DSA (Mauiyyedi et al., 2002). If C4d staining misses some cases of antibody-
mediated injury, and the presence of alloantibody does not identify which grafts are under‐
going antibody-mediated damage, we need new methods for identifying which kidneys are
being damaged by alloantibody.
7.3. Alternative markers (New diagnostic tools)
7.3.1. Endothelial-associated transcripts (ENDATs) as a new marker for CAMR
Recognizing the key role of endothelial changes in AMR, it was postulated by Sis and collea‐
gues (Sis et al., 2009) that altered expression of endothelial genes in biopsies from patients with
alloantibody would identify kidneys incurring antibody-mediated damage and at risk for graft
loss, whether they were C4d+ or negative. They explored whether expression of endothelial
genes was increased in biopsies manifesting antibody-mediated graft injury, and whether such
changes could be seen in C4d negative as well as C4d positive biopsies. They identified 119
endothelial-associated transcripts (ENDATs) from literature, and studied their expression by
microarrays in 173 renal allograft biopsies for cause.
Mean ENDAT expression was increased in all  rejection but was higher in AMR than in
T-cell-mediated rejection and correlated with histopathologic lesions of AMR, and alloan‐
tibody. Many individual ENDATs were increased in AMR and predicted graft loss. Kid‐
neys  with  high  ENDATs  and  antibody  showed  increased  lesions  of  AMR  and  worse
prognosis in comparison to controls. Only 40% of kidneys with high ENDAT expression
and chronic AMR or graft loss were diagnosed by C4d positivity. High ENDAT expres‐
sion  with  antibody  predicts  graft  loss  with  higher  sensitivity  (77%  versus.  31%)  and
slightly  lower  specificity  (71%  vs.  94%)  than  C4d.  The  results  were  validated  in  inde‐
pendent  set  of  82  kidneys.  They  concluded  that  in  patients  with  alloantibodies,  abnor‐
malities in expression of endothelial genes identify not only C4d+ AMR but some kidney
transplants  developing  antibody  associated  graft  injury  despite  negative  C4d  staining
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and that ENDAT changes in renal transplants occur in rejection and in other forms of re‐
nal injury, and their impact on transplant glomerulopathy and graft loss is principally in
patients with circulating HLA antibodies. The elevation of the ENDATs is of value in de‐
termining which biopsies for cause in patients with antibody may have antibody-mediat‐
ed injury, even when they are C4d negative. Based on their study, the combined burden
of C4d+ and C4d negative AMR accounts for the majority of graft losses in kidney trans‐
plants biopsied for clinical indications (17 of 26, 65%). ENDAT expression in biopsy pro‐
vides a new tool for understanding the pathogenesis of late kidney graft loss and AMR,
and for  predicting graft  outcomes and defining AMR even in  C4d negative  biopsies  in
patients with antibodies (Sis et al., 2009).
7.3.2. TRIB1as a new non-invasive marker for CAMR
The discovery of novel and less invasive surrogate biomarkers of acute cellular rejection,
for which urine levels of  Granzyme B and FOXP3 transcripts have been shown to have
diagnostic and prognostic value (Muthukumar et al., 2005; Veale et al., 2006), has proved
successful.  Such  an  approach  in  the  case  of  the  different  causes  of  late  graft  failure
would facilitate  the  introduction of  more  targeted immunosuppression and thereby im‐
prove  long-term  outcome.  Ashton-Chess  and  colleagues  (Ashton-Chess  et  al.,  2008)  set
out  to  discover  novel  minimally invasive biomarkers  of  more precise  histologic  diagno‐
ses  of  late  graft  scarring.  Using a  literature gene-set  comparison approach for  late  graft
injury,  they  identified  TRIB1,  a  human  homolog  of  Drosophila  tribbles,  (Grosshans  &
Wieschaus,  2000)  as  a  potentially  informative  biomarker.  TRIB1  is  a  scarcely  character‐
ized member of the tribbles family that has been shown to be a potent regulator of cell
signaling18 in various cells lines. It was determined that TRIB1 is expressed primarily by
antigen-presenting  cells  (APC)  and  activated  endothelial  cells  (EC).  TRIB1  differs  from
the other minimally invasive biomarkers of transplant rejection described to date that are
of  T/NK cell  origin,  (Muthukumar  et  al.,  2005;  Seiler  et  al.,  2007;  Veale  et  al.,  2006)  in
that it is expressed primarily by APC as well as EC.
They explored the potential of TRIB1 as a tissue, peripheral blood, and urine biomarker by
measuring its mRNA profiles in graft biopsies, blood, and urine from healthy volunteers and
kidney transplant recipients with different histologic and/or clinical diagnoses. For testing this,
mRNA expression in 76 graft biopsies, 71 blood samples, and 11 urine samples were profiled
from independent cohorts of renal transplant patients with different histologic diagnoses
recruited at two European centers. TRIB1 but not TRIB2 or TRIB3 was found to be a potential
blood and tissue (but not urine) biomarker of chronic antibody-mediated rejection. Moreover,
TRIB1 mRNA in the blood was more specific and sensitive for diagnosing chronic AMR than
TRIB1 mRNA in biopsies.
TRIB1 mRNA levels in peripheral blood mononuclear cells discriminated patients with chronic
antibody-mediated rejection from those with other types of late allograft injury with high
sensitivity and specificity, suggests TRIB1 to be a marker of an active immune response.
Overall, these data support the potential use of TRIB1 as a biomarker of chronic antibody-
mediated allograft failure.
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8. Management of antibody mediated rejection
Unfortunately, no immunosuppressive standard for the prevention or therapy of alloantibody
production has been established yet. Although based on very limited evidence, acute humoral
rejections are frequently treated with a switch to tacrolimus, plasmapheresis or immunoad‐
sorption, as well as T- and B-cell-depleting antibodies. However, the best therapeutic approach
for C4d-positive, chronic humoral kidney rejection associated with an unfavourable prognosis
remains completely unclear. Neither the dose nor the best drug combination for the therapy
of an established humoral rejection is based on solid evidence. Although various immuno‐
suppressive drugs can reduce the number of acute rejection ns via inhibition of the T-cell
response, only very few data are available regarding immunosuppressive drugs affecting the
humoral alloresponse after organ transplantation.
8.1. Intravenous immunoglobulins (IVIG)
The immunomodulatory effects of IVIG are multiple, and the exact mechanisms are not
elucidated. However, effective alloantibody inhibition by IVIG was shown in the context of
desensitization protocols only relying on high dose IVIG treatment (Jordan et al., 2003). IVIG
inhibits mixed lymphocyte reactions and induces apoptosis mainly in B cells (Toyoda et al.,
2004). There are numerous proposed mechanisms how IVIG exerts its immunomodulatory
action. They include modification of circulating alloantibody concentration through induction
of antiidiotypic circuits, antigen binding through the Fab part of the immunoglobulin mole‐
cule, Fc receptor-mediated interaction with antigen-presenting cells to block T- and B-cell
activation, and inhibition of complement activity (Jordan et al., 2006).
In vivo, IVIG reduces the number of B cells and monocytes, and it reduces CD19, CD20 and
CD40 expression by B cells, thereby modulating B-cell signaling (Jordan et al., 2003). IVIG
inhibits binding of donor-reactive antibodies to target cells in ∼80% of patients, indicating that
the presence of blocking antibodies might explain the efficacy of IVIG, although the mechanism
is not known (Jordan et al., 2003). Billing and colleagues (Billing et al., 2008) studied Six
pediatric renal transplant recipients with CAMR and gave them four weekly doses of IVIG (1
g/kg body weight per dose), followed by a single dose of rituximab (375 mg/m2 body surface
area) 1 week after the last IVIG infusion. Median glomerular filtration rate during 6 months
before intervention dropped by 25 (range, 11–26) mL/ min/1.73m2 (P<0.05) and increased in
response to antihumoral therapy by 21 (-14 to+30) 6 months (P<0.05) and by 19 (-14 to+_23)
mL/min/1.73 m2 12 months (P=0.063) after start of treatment. Glomerular filtration rate
improved or stabilized in 4 patients; the two non-responders had the highest degree of
transplant glomerulopathy, the highest degree of C4d deposition in peritubular capillaries and
pronounced interstitial inflammation. The treatment regimen was well tolerated. Another
study conducted by Fehr and colleagues (Fehr et al., 2009) who reported four kidney allograft
recipients suffering from chronic AMR 1 to 27 years post-transplant, who were treated with a
combination of rituximab and intravenous immunoglobulin (IVIG) with improved kidney
allograft function in all four patients, whereas donor-specific antibodies were reduced in 2 of
4 patients.
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8.2. Rituximab
Rituximab, a chimeric monoclonal anti-CD20 antibody directed against B cells, prevents new
antibody production by depletion of B cells as precursors of mature plasma cells in the
circulation and the lymphoid tissue {although, some recent reports demonstrated that
depletion in secondary and tertiary lymphoid structures is far less efficient and may not affect
an ongoing localized humoral immune response (Genberg et al., 2006; Thaunat et al., 2008)},
prevention of B-cell proliferation, and induction of apoptosis and lysis of B cells through
complement-dependent and -independent mechanisms (Salama & Pusey, 2006). Rituximab
binds CD20 at the surface of precursor and mature B cells and leads to transient B-cell
depletion, with typical B-cell recovery after 6–12 months in more than 80% of patients, although
the degree of depletion is highly variable and is observed for up to 24 months in some
individuals (Sureshkumar et al., 2007).An additional potential mechanism of action of
rituximab is the direct targeting of CD20-positive cells that infiltrate the graft (Steinmetz et al.,
2007). Preliminary studies indicate that rituximab decreases the concentration of pre-existing
and post-transplantation antibodies (Gloor et al., 2003; Vieira et al., 2004). Conclusions and
extrapolations from these studies are limited, because rituximab is usually combined with
other therapies in these small and uncontrolled trials. The risk of bacterial infection as a result
of immunoglobulin deficiency is also an important consideration. Based on the pathophysio‐
logic condition of this rejection process and efficacy of rituximab in B cells and antibody-
mediated autoimmune diseases (Eisenberg & Albert, 2006; Levesque & St Clair, 2008), a
combination treatment with rituximab/IVIG represents a logical approach.
8.3. Mycophenolic acid and sirolimus
In a multicenter study, MMF in combination with cyclosporine resulted in significantly lower
frequencies of HLA antibodies when compared with azathioprine and cyclosporine treatment
(Terasaki & Ozawa, 2004). Moreover, MMF was described to be effective in inhibiting primary
antigen-specific antibody responses in renal transplant patients (Rentenaar et al., 2002). Heidt
et al (Heidt et al., 2008) stimulated purified human B cells devoid of T cells with CD40L
expressing L cells, or by anti-CD40mAb with or without Toll-like receptor triggering, all in the
presence of B-cell activating cytokines. These three protocols resulted in various degrees of B-
cell stimulation. Then, they added four commonly used immunosuppressive drugs (tacroli‐
mus, cyclosporin, mycophenolic acid [MPA], and rapamycin) to these cultures and tested a
variety of parameters of B-cell activity including proliferation, apoptosis induction, and both
IgM and IgG production. They found that MPA was extremely potent in inhibiting both
proliferation and immunoglobulin production. Moreover, these effects persisted when MPA
was added to already activated B cells, implying that an ongoing B-cell response may be
dampened by MPA, whereas calcineurin inhibitors are ineffective. MPA levels used are lower
than levels that are usually achieved physiologically.
In the same in vitro experiments, rapamycin, like MMF, was described to be extremely potent
in inhibiting humoral responses. Rapamycin was the most effective drug tested, as it inhibited
not only B-cell proliferation and immunoglobulin production, but also inhibited the number
of immunoglobulin producing cells. None of the other drugs tested were capable of decreasing
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the number of immunoglobulin producing cells. By contrast, tacrolimus and cyclosporin
marginally inhibited B-cell proliferation and immunoglobulin production, and the extent of
inhibition depended on the degree of the B-cell stimulation.
8.4. Bortezomib
While the B cell-depleting anti-CD20 antibody rituximab is increasingly incorporated in
treatment protocols of humoral rejection (Faguer et al., 2007), this reagent is neither effective
in eliminating antibody-producing plasma cells (PC) – either newly created from memory or
naıïve B cells or from those that existed prior to transplant- nor does it decrease circulating
antibody titers (Singh et al., 2009). For an effective blockade of alloantibody formation, a
specific PC-depleting reagent would be desirable. Bortezomib (BZ), a selective inhibitor of the
26S proteasome, has been approved by FDA for the treatment of relapsed multiple myeloma.
Mechanisms of BZ action include inhibition of NF-κ B and cytokine expression as well as
induction of apoptosis as a result of activation of the terminal unfolded protein response
(Meister et al., 2007). Susceptibility to BZ-induced apoptosis is related to the high immuno‐
globulin synthesis rate of PCs associated with accumulation of unfolded proteins/DRiPs
inducing endoplasmatic reticulum stress (Meister et al., 2007). Moreover, BZ not only acted on
the humoral response but also effectively inhibited the influx of MHC class II+ cells, mono‐
cytes/macrophages, CD8+ as well as CD4+ T cells. In animal models, Vogelbacher and
colleagues (Vogelbacher et al., 2010) found that combination of Bortezomib and sirolimus
inhibit the chronic active antibody-mediated rejection in experimental renal transplantation
in the rat. In humans, data are lacking. In one case report, Bortezomib failed to treat CAMR
even after treatment with rituximab and IVIG.
Perry and colleagues (Perry et al., 2009) described two sensitized patients with AMR treated
in February 2007 using a combination of bortezomib and multiple plasmapheresis. Both
patients had resolution of AMR and decreased serum DSA levels months after treatment.
Neither developed transplant glomerulopathy. In a slightly different clinical setting, Everly
and colleagues (Everly et al., 2008) used bortezomib to treat six patients who had combined
AMR and cellular rejection occurring from 3 months to 7.5 years after transplant. All six
patients showed resolution of AMR with a decrease in DSA levels after treatment. Unfortu‐
nately, three of the six patients developed transplant glomerulopathy. Flechner and coworkers
(Flechner et al., 2010) treated 20 cases (16 kidney-only and 4 kidney-combined organ recipients)
with AMR 19.8 months (range 1-71 months) posttransplant using a combined regimen of
intravenous corticosteroids followed by a 2-week cycle on days 1-4-8-11 of plasmapheresis and
1.3 mg/m2 bortezomib; then 0.5 mg/kg intravenous immunoglobulin four times. They found
that the bortezomib-containing regimen demonstrated activity in AMR but seems to be most
effective before the onset of significant renal dysfunction (serum creatinine <3 mg/dL) or
proteinuria (<1 g/day).
Compared to rituximab, Waiser and colleagues (Waiser et al., 2012) found that patients with
AMR treated with bortezomib had better graft survival At 18 months after treatment (P = 0.071)
and renal function at 9 months was superior in patients treated with bortezomib as compared
to rituximab-treated patients (P= 0.008). Whereas these early clinical experiences with protea‐
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some inhibition are encouraging, the lack of controls is a major limitation in assessing true
efficacy. In addition, since even successfully treated AMR can still result in the development
of chronic transplant glomerulopathy, the prevention of AMR might be a more important goal
of these types of therapies.
8.5. Eculizumab (Terminal complement inhibition with eculizumab)
Almost all episodes of AMR are accompanied by evidence of early complement activation as
demonstrated by C4d staining of the peritubular capillaries (Burns et al., 2008). However, the
exact role of complement in the pathogenesis of AMR is unclear. Eculizumab is a humanized
monoclonal antibody with high affinity for C5 and thus blocks the activation of terminal
complement. Eculizumab is approved by the FDA for the treatment of paroxysmal nocturnal
hemoglobinuria. Locke et al. (Locke et al., 2009) reported the successful treatment of a patient
with severe AMR using eculizumab. Stegall and colleagues reported their initial experience
with eculizumab treatment at the time of transplant showing that blockade of terminal
complement prevented the development of AMR in patients who developed high levels of
DSA post transplant (Stegall et al., 2009). Stegall et al also examined the efficacy of eculizumab
in the prevention AMR in sensitized renal transplant recipients with a positive crossmatch
against their living donor (Stegall et al., 2011). The incidence of biopsy-proven AMR in the first
3 months posttransplant in 26 highly sensitized recipients of living donor renal transplants
who received eculizumab posttransplant was compared to a historical control group of 51
sensitized patients treated with a similar plasma exchange-based protocol without eculizu‐
mab. The incidence of AMR was 7.7% in the eculizumab group compared to 41.2% in the
control group (P = 0.0031). Eculizumab also decreased AMR in patients who developed high
levels of DSA early after transplantation that caused proximal complement activation. With
eculizumab, AMR episodes were easily treated with plasma exchange reducing the need for
splenectomy. On 1-year protocol biopsy, transplant glomerulopathy was found to be present
in 6.7% eculizumab-treated recipients and in 35.7% of control patients (P = 0.044).
Taken together, these studies suggest that terminal complement activation may play a critical
role in the pathogenesis of early AMR. Thus, eculizumab may provide an attractive approach
to the prevention of AMR.
8.6. Future therapies with new targets
8.6.1. B cells
Memory B cells are heterogeneous but have cell-surface markers (CD24, CD27, CD43 and
CD79b) that are potential therapeutic targets (McHeyzer-Williams & McHeyzer-Williams,
2005). B cells also express TACI (transmembrane activator and calcium-modulating cyclophi‐
lin-ligand interactor), BCMA (B-cell maturation antigen) and BAFF receptor (B-cell-activating
factor receptor), all of which are members of the TNF-receptor family that are triggered by the
ligands BAFF and APRIL (a proliferation inducing ligand), which are expressed at the cell
surface of DCs (Craxton et al., 2003). A soluble TACI–immunoglobulin fusion protein blocks
B-cell development by inhibiting the interaction between B cells and DCs (Gross et al., 2001).
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These cell-surface markers might be useful targets to prevent the development of B cells into
plasma cells.
8.6.2. Plasma cells
Normal  plasma cells  express  little  or  no CD20 and are  therefore  resistant  to  rituximab-
mediated  depletion.  Several  cell-surface  molecules  that  are  expressed  by  plasma  cells
might  be  considered  as  drug  targets  —  syndecan-1  (CD138),  CD38,  α4β1-integrin
(CD49d–CD29) and CXC-chemokine receptor 4 (CXCR4) — although none of these is en‐
tirely plasma-cell  specific.  Plasma-cell  longevity is thought to be an extrinsic phenomen‐
on that  is  mediated by survival  signals  delivered by bone-marrow stromal cells  (Colvin
& Smith, 2005). Because the transcription factors BLIMP1 (B-lymphocyte-induced matura‐
tion protein 1)  and XBP1 (X-box-binding protein 1)  (as  well  as  the  repression of  PAX5,
paired box gene 5)  are required to maintain plasma-cell  function,  their  inhibition might
result in the loss of plasma-cell function (Shapiro-Shelef & Calame, 2005).
8.6.3. Complement antagonists
Complement antagonists could prevent the acute pathological effects of complement activa‐
tion. For example, soluble CR1 delays antibody-mediated rejection in xenograft models but is
insufficient to prevent graft rejection completely (Azimzadeh et al., 2003). Other complement
antagonists, such as C5-specific antibody, which blocks activation of C5 and formation of both
C5a and the MAC, are in ongoing evaluation. Transgenic expression of human complement-
regulatory proteins (DAF and CD59) in pigs has shown potency for preventing xenograft
rejection (Menoret et al., 2004), but the relevance of these studies to allografts needs to be
extended and tested.
9. Summary
Immunologic barriers once considered insurmountable are now consistently overcome to
enable more patients to undergo organ transplantation. Alloantibodies are a substantial
obstacle to short- and long-term graft survival. To prevent or reduce alloantibody titres, more
insights are needed to improve our understanding of the regulation of B cells and the devel‐
opmental and differentiation pathways of memory B cells and plasma cells.
Several important issues regarding AMR remain. First, the immunologic mechanisms respon‐
sible for the development of high levels of DSA are still unclear. The contribution of memory
B cells versus the role of pre-existing PCs has important therapeutic implications since each
may have a differential sensitivity to various agents.
Whereas several new therapeutic approaches have emerged, more extensive study and follow-
up are needed to determine if these apparent advances will improve the outcomes of AMR.
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